Next-Gen Complement Therapeutics Market Poised for Explosive Growth to $23.04 Billion by 2031.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Next-Generation Complement Therapeutics Market Size, Share & Trends Analysis Report By Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, and Neuromyelitis Optica), Therapeutic Area (Cardiovascular, Genetic, Hematological And Vascular, Infectious, Neurological), Molecule Type, Type Of Therapy, Route Of Administration (Intravenous, Oral, And Subcutaneous), Region, Market Outlook And Industry Analysis 2031"

According to the latest research by InsightAce Analytic, the global next-generation complement therapeutics market is valued at US$ 6.9 Bn in 2022, and it is expected to reach US$ 23.04 Bn by 2031, with a CAGR of 14.39% during the forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2269

The complement system recreates a crucial role in innate immunity and maintaining tissue homeostasis, and it protects against infection and flags apoptotic cells and debris for disposal. This complement system also contributes to the pathogenesis of inflammatory and autoimmune diseases and has driven industries and research institutes to develop novel 'next-generation' therapeutic drugs targeting different proteins and functions of the complement system.

Factors such as the high prevalence of immune system and infectious diseases, ongoing clinical trials related to complement-targeted therapeutics, growing clinical research activities for developing complement therapeutic drugs, fast adoption of next-generation technologies, availability of well-established healthcare infrastructures are projected to expand the growth of the market during the forecast years. Increasing clinical studies on complement-targeted therapeutics to treat diseases such as COVID-19, cardiac transplantation rejection, paroxysmal nocturnal hemoglobinuria and others are expected to enhance the growth opportunities in the global next-generation complement therapeutics market. On the other hand, an undiagnosed population with complement deficiency may restrain market adoption over the forecast period.

Regionally, North America is expected to lead the next-generation complement therapeutics market over the forecast period (2022-2031), owing to the fast adoption of next-generation technologies and increasing R&D investments to develop novel complement-targeted drug therapeutics. Apart from this, Europe holds the second position in this market regarding revenue share.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Key market players operating in the next-generation complement therapeutics market include Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, and UCB, among others.

Key Developments In The Market:
• In Oct 2022, Amgen announced that the acquisition of ChemoCentryx, Inc. has been effectively finalized. The acquisition comprises TAVNEOS®, an orally administered selective complement 5a receptor inhibitor that received adjunctive therapy approval from the U.S. Food and Drug Administration (FDA) in October 2021. The standard of care for adults with severe active ANCA-associated vasculitis typically consists of cyclophosphamide or rituximab immunosuppressant therapy. TAVNEOS® is intended to supplement this regimen. The acquisition also includes an oral checkpoint for cancer and three early-stage drug candidates that target chemoattractant receptors and other inflammatory diseases, in addition to TAVNEOS®.
• In Feb 2022, Enjaymo™ (sutimlimab-jome) was granted approval by the U.S. Food and Drug Administration (FDA) for the purpose of reducing the necessity for red blood cell transfusions in adults diagnosed with cold agglutinin disease (CAD) caused by hemolysis. As the first and only approved treatment for CAD, Enjaymo functions by impeding the process of red blood cell degradation, also known as hemolysis.Enjaymo was granted approval in the United States on the basis of positive results from the CARDINAL study, a 26-week open label, single arm pivotal Phase 3 trial involving 24 patients with CAD and a recent history of blood transfusion.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2269

Market Segments
Global Next-Generation Complement Therapeutics Market, by Target Disease Indication, 2022-2031 (Value US$ Mn)
• Atypical Hemolytic Uremic Syndrome
• Paroxysmal Nocturnal Hemoglobinuria
• Cardiac Transplantation Rejection
• Cold Agglutinin Disease
• COVID-19
• Generalized Myasthenia Gravis
• Guillain-Barre Syndrome
• Hereditary Angioedema
• Neuromyelitis Optica
Global Next-Generation Complement Therapeutics Market, by Therapeutic Area, 2022-2031 (Value US$ Mn)
• Cardiovascular
• Genetic
• Hematological and Vascular
• Infectious
• Neurological and Neuromuscular Disorders
Global Next-Generation Complement Therapeutics Market, by Molecule Type, 2022-2031 (Value US$ Mn)
• Biologic
• Small Molecule
Global Next-Generation Complement Therapeutics Market, by Type of Therapy, 2022-2031 (Value US$ Mn)
• Monotherapy
• Combination Therapy
Global Next-Generation Complement Therapeutics Market, by Route of Administration, 2022-2031 (Value US$ Mn)
• Intravenous
• Oral
• Subcutaneous
Global Next-Generation Complement Therapeutics Market, by Region, 2022-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• U.S.
• Canada
Europe Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2269

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.